Alan Fullerton advised Biopure (Nasdaq:BPUR), a developer of oxygen therapeutics

Alan Fullerton advised Biopure (Nasdaq:BPUR), a developer of oxygen therapeutics for veterinary and human use, on its sale to OPK Biotech.

Biopure Corp. (NASDAQ: BPUR) entered into an agreement with OPK Biotech LLC for the sale of substantially all of its assets.  Cambridge, Massachusetts-based Biopure develops and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body’s tissues.

OPK Biotech LLC, a Delaware company, purchased Biopure’s operating assets and its 50 percent interest in a partnership that owns the Cambridge building that houses Biopure’s headquarters, and some laboratory space.

About Mirus Capital Advisors

Mirus Capital Advisors provides investment banking solutions to corporate clients in technology, business services, manufacturing, consumer products, health care and the resort & hospitality industry. Since 1987, Mirus has provided corporate finance advisory services on engagements including mergers, acquisitions, divestitures, recapitalizations and valuations.